- Northwell Health Fertility
- United States of America
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.
Register
Recent Comments
Very excited to see this data published; however I would like to note that NIPT is not the most appropriate follow-up test for women who become pregnant from a mosaic embryo and found its inclusion in the data as proof of a good/"normal" outcome puzzling. Firstly, NIPT is a screening test that uses cell-free fetal DNA, which is placental in origin and therefore arises from the trophectoderm of the embryo. While concordant with the fetus in most cases, it may be normal in the presence of a chromosomally abnormal fetus and is particularly problematic if confined placental mosaicism exists. Second, most NIPT platforms include only chromosomes 13, 18, 21 and the sex chromosomes and therefore give you no information on other chromosome aneuploidies that may have been mosaic in the embryo on PGT-A. Finally, while a whole-genome NIPT is currently available, there remain a lot of unknowns about the performance of this screening test in terms of its positive predictive value (PPV) and negative predictive values (NPV). False-positives are likely on this testing, which would push a patient with a very precious pregnancy to diagnostic testing through CVS or amniocentesis. Amniocentesis remains the optimal follow-up test for patients who become pregnant (with 50 cell karyotype and microarray if a segmental mosaic was transferred!). NIPT must be offered with care and proper counseling regarding the limitations. Thanks for this exciting paper!